AKBA.NASDAQAkebia Therapeutics, INC
DEF 14A: Akebia Therapeutics Seeks Stockholder Approval for Increased Share Issuance Under Incentive Plan
Sentiment:
Proxy Statement
Akebia Therapeutics is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance by 9,800,000.
Summary
- Akebia Therapeutics is seeking stockholder approval to amend its 2023 Stock Incentive Plan, increasing the share pool by 9,800,000 shares.
- The amendment aims to attract, retain, and motivate key employees through equity-based compensation.
- If approved, the new shares would represent approximately 9.9% of the company's outstanding shares as of March 31, 2024.
- The company intends to use the additional shares for equity awards to employees, non-employee directors, consultants, and advisors.
- The company estimates the proposed share pool will cover equity awards for approximately two years, excluding new-hire inducement grants.
- As of March 31, 2024, the company had 16,242,463 outstanding stock options with a weighted average exercise price of $3.73 and 6,054,131 outstanding RSUs.
- The company's overhang as of March 31, 2024, was 16.2%, which would increase to 20.86% if the amendment is approved.
- The average burn rate for the past three years (2021-2023) was 4.63%.
Sentiment
Score: 7
Explanation: The document is primarily factual and informative, with a slightly positive tone due to the company's efforts to attract and retain talent and align interests with stockholders.
Positives
- The amendment is expected to help attract and retain key employees.
- Equity-based compensation aligns employee and director interests with stockholder interests.
- The Amended Plan includes features consistent with sound corporate governance, such as no evergreen provision and a clawback policy.
Negatives
- Approval of the amendment will increase the company's overhang, potentially diluting existing stockholders' equity.
- If the amendment is not approved, the company may need to increase cash compensation, reducing resources for other business needs.
Risks
- If the amendment is not approved, the company may struggle to attract and retain talent in a competitive market.
- The company's equity compensation needs must be balanced against the dilutive effect on stockholders.
Future Outlook
The company plans to continue reviewing and advancing its efforts related to ESG matters with the support and oversight of its Board of Directors and the Nominating and Corporate Governance Committee.
Industry Context
The document mentions that the company's compensation practices are consistent with those of other pharmaceutical companies in its peer group and other companies that it competes with for talent.
Comparison to Industry Standards
- The Compensation Committee compares our executive compensation against a peer group to determine market trends and competitiveness.
- The 2023 Peer Group was developed using an objective process based on specific metrics that were used to evaluate and, as needed update, our approved peer group for 2022, including to identify potential new companies for inclusion.
- An initial group was evaluated based on U.S. based, biotechnology and pharmaceutical companies publicly traded on a major exchange.
- The group was further refined to focus on commercial stage companies in a comparable range to our then market capitalization, operating expenses and headcount.
- Lastly, the group was further filtered for companies in the same or a similar location and therapeutic area.
- To arrive at competitive market compensation, market data collected from the peer group and data from comparably sized publicly traded commercial life sciences companies from the Radford Global Compensation Database was incorporated appropriately to form a composite assessment.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Senior Vice President, Chief Financial Officer and Treasurer | David A. Spellman | Ellen E. Snow | July 2023 | Spellman separated from the Company in June 2023 |
| Senior Vice President, Chief Financial Officer and Treasurer | Ellen E. Snow | TBD | March 2024 | Snow and the Company mutually agreed that she would transition from the Company in March 2024. |
| Senior Vice President, Chief Operating Officer | Michel Dahan | TBD | June 28, 2024 | Dahan will separate from the Company effective as of June 28, 2024 |
| Senior Vice President, Chief Legal Officer and Corporate Secretary | Nicole R. Hadas | TBD | June 14, 2024 | Hadas will separate from the Company effective as of June 14, 2024 |
| Senior Vice President, Chief Commercial Officer | TBD | Nicholas Grund | January 2024 | New Hire |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Stock Incentive Plan | Proposed amendment to the 2023 Stock Incentive Plan to increase the number of shares available for issuance by 9,800,000. | Upon Stockholder Approval | Aims to attract, retain, and motivate key employees; may dilute existing stockholders' equity. |
| Adoption of Clawback Policy | Adoption of a Dodd-Frank Compensation Recovery Policy in accordance with Nasdaq listing standards and Rule 10D-1 under the Exchange Act. | November 2023 | Allows the company to recoup erroneously awarded compensation from executive officers in the event of an accounting restatement. |
| Revisions to Policy With Respect to Related Person Transactions | The Board of Directors reviewed and approved certain revisions to this policy to ensure that the policy reflected current corporate best practices. | November 2023 | Governs the review and approval of any transaction, arrangement or relationship in which we are a participant, the amount involved exceeds $120,000, and one of our executive officers, directors, director nominees or 5% stockholders (or their immediate family members), each of whom we refer to as a related person, has a direct or indirect material interest. |
Stakeholder Impact
- Approval of the amendment could dilute existing stockholders' equity.
- Failure to approve the amendment could hinder the company's ability to attract and retain talent, potentially impacting long-term performance.
- The company's ESG initiatives aim to benefit patients, employees, communities, and the environment.
Next Steps
- Stockholder vote on the proposed amendment to the 2023 Stock Incentive Plan.
- If approved, the company intends to register the additional shares by filing a Registration Statement on Form S-8.
Key Dates
| Date | Description |
|---|---|
| 1995 | U.S. Private Securities Litigation Reform Act of 1995 |
| 2010 | Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 |
| 2013 | Ernst & Young LLP has served as our independent registered public accounting firm since 2013. |
| 2020 | The Companys 2020 annual meeting of stockholders, stockholders voted to hold an advisory vote every year. |
| 2021 | The average burn rate for the past three years (2021-2023) was 4.63%. |
| 2023-01-01 | The 2023 bonus plan period under the Cash Incentive Plan covered the 12-month period beginning on January 1, 2023 and ending on December 31, 2023. |
| 2023-03-14 | Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 14, 2024 |
| 2023-03-15 | Ms. Zumwalt joined, and Mr. Frieson became the Chairperson, of the Nominating and Corporate Governance Committee on March 15, 2023. |
| 2023-03-31 | As of March 31, 2024, the company had 16,242,463 outstanding stock options with a weighted average exercise price of $3.73 and 6,054,131 outstanding RSUs. |
| 2023-04-27 | The Board of Directors adopted the Amended and Restated Non-Employee Director Compensation Program, effective April 27, 2023 |
| 2023-05 | In May 2023, Mr. Dahan and Ms. Hadas each vested in 200,000 PSUs in connection with the achievement of a corporate performance milestone, the signing of a definitive license agreement. |
| 2023-06-06 | The Board of Directors adopted the Second Amended and Restated Non-Employee Director Compensation Program, effective June 6, 2023 |
| 2023-06-28 | Pursuant to the retention and separation agreements, each of Mr. Dahan and Ms. Hadas will separate from the Company effective as of June 28, 2024 and June 14, 2024, respectively. |
| 2023-07 | Ms. Snow became our Senior Vice President, Chief Financial Officer and Treasurer in July 2023. |
| 2023-11 | In November 2023, we adopted a Dodd-Frank Compensation Recovery Policy, or Clawback Policy, in accordance with the Nasdaq listing standards and Rule 10D-1 under the Exchange Act |
| 2024-01-01 | The Board of Directors adopted the Third Amended and Restated Non-Employee Director Compensation Program, effective January 1, 2024 |
| 2024-01-24 | On April 24, 2024, upon the recommendation of the Compensation Committee, our Board of Directors adopted, subject to stockholder approval, the Amendment. |
| 2024-03 | Ms. Snow and the Company mutually agreed that she would transition from the Company in March 2024. |
| 2024-03-27 | On March 27, 2024, the U.S. Food and Drug Administration, or FDA, approved Vafseo (vadadustat) tablets for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. |
| 2024-04-09 | The Board of Directors fixed the record date for the Annual Meeting as of 5:00 p.m. Eastern Time on April 9, 2024 |
| 2024-04-25 | We are mailing to our stockholders a Notice of Internet Availability of Proxy Materials, or Notice, instead of a paper copy of our proxy materials and our 2023 Annual Report to Stockholders, or Annual Report, on or about April 25, 2024. |
| 2024-06-06 | The 2024 Annual Meeting of Stockholders, or the Annual Meeting, of Akebia Therapeutics, Inc., or the Company or Akebia, will be held on Thursday, June 6, 2024, at 10:00 a.m. Eastern Time in a virtual meeting format via live webcast. |
| 2025 | Assuming the date of our 2025 annual meeting of stockholders is not so advanced or delayed, for stockholder proposals to be brought before the 2025 annual meeting of stockholders in accordance with our advance notice provisions, the required notice must be received by our Corporate Secretary at our principal executive offices no earlier than February 6, 2025 and no later than March 8, 2025. |
Keywords
stock incentive plan, equity compensation, share issuance, stockholders, dilution, overhang, burn rate, executive compensation, talent retention, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.